Display options
Cite
Nathanson D, Frick M, Ullman B, et al. Exenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failure. Diabetol Metab Syndr. 2016;8:5doi: 10.1186/s13098-015-0116-2.
Nathanson, D., Frick, M., Ullman, B., & Nyström, T. (2016). Exenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failure. Diabetology & metabolic syndrome, 85. https://doi.org/10.1186/s13098-015-0116-2
Nathanson, David, et al. "Exenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failure." Diabetology & metabolic syndrome vol. 8 (2016): 5. doi: https://doi.org/10.1186/s13098-015-0116-2
Nathanson D, Frick M, Ullman B, Nyström T. Exenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failure. Diabetol Metab Syndr. 2016 Jan 12;8:5. doi: 10.1186/s13098-015-0116-2. eCollection 2016. PMID: 26759609; PMCID: PMC4709886.
Copy Download .nbib Format: NLM
Share it on

Diabetol Metab Syndr. 2016 Jan 12;8:5. doi: 10.1186/s13098-015-0116-2. eCollection 2016.

Exenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failure.

Diabetology & metabolic syndrome

David Nathanson, Mats Frick, Bengt Ullman, Thomas Nyström

Affiliations

  1. Department of Clinical Science and Education, Karolinska Institutet, 11883 Stockholm, Sweden ; Department of Endocrinology and Diabetology, Södersjukhuset, 11883 Stockholm, Sweden.
  2. Department of Clinical Science and Education, Karolinska Institutet, 11883 Stockholm, Sweden ; Department of Cardiology, Södersjukhuset, 11883 Stockholm, Sweden.

PMID: 26759609 PMCID: PMC4709886 DOI: 10.1186/s13098-015-0116-2

Abstract

BACKGROUND: The vascular effects exerted by GLP-1 are mediated by several synergistic mechanisms such as involvement of nitric oxide and natriuresis. Recently, it was demonstrated that atrial natriuretic peptide (ANP) is essential for the glucagon-like peptide-1 (GLP-1)-stimulated vascular smooth muscle relaxation that mediates anti-hypertensive action in rodents. Therefore a GLP-1-ANP axis has been suggested. The aim of this study was to investigate whether this effect can be demonstrated in patients with type 2 diabetes and congestive heart failure.

METHODS: The study was a post hoc analysis of a randomized double-blinded, placebo-controlled trial. Twenty male patients with type 2 diabetes and congestive heart failure were randomized to receive a 6-h infusion of exenatide or placebo. Cardiac filling pressures were measured by right heart catheterization, and plasma levels of ANP, N-terminal pro-brain natriuretic peptide, and exenatide were measured at baseline and at the end of the exenatide infusion.

RESULTS: Exenatide infusion resulted in a significant decrease of circulating ANP levels compared with placebo, concomitant with a decrease in pulmonary capillary wedge pressure (PCWP), pulmonary artery pressure (PAP) and right arterial pressure (RAP), and increased cardiac output. There was no correlation between plasma ANP levels and exenatide levels. A negative correlation between ANP levels and PCWP, PAP, and RAP, which remained significant after adjustment for plasma exenatide levels, was demonstrated during exenatide infusion.

CONCLUSIONS: Exenatide infusion decreases cardiac filling pressure and ANP levels. The reduction of ANP levels was primarily because of the reduction in cardiac filling pressure, independent of exenatide levels. It seems unlikely that this was mediated via ANP.

TRIAL REGISTRATION: http://www.isrctn.org/ISRCTN47533126.

Keywords: Atrial natriuretic peptide; Exenatide; GLP-1; Heart failure; Type 2 diabetes

References

  1. Cardiovasc Diabetol. 2014 Feb 05;13:36 - PubMed
  2. Cardiovasc Diabetol. 2014 Apr 02;13:69 - PubMed
  3. Can J Physiol Pharmacol. 1983 Dec;61(12):1462-6 - PubMed
  4. J Card Fail. 2006 Dec;12(9):694-9 - PubMed
  5. Nat Med. 2013 May;19(5):567-75 - PubMed
  6. BMJ Open. 2013 Jan 24;3(1):null - PubMed
  7. Pharmacol Ther. 2004 Jun;102(3):223-41 - PubMed
  8. Circ Res. 2014 May 23;114(11):1788-803 - PubMed
  9. Cardiovasc Res. 1996 Nov;32(5):909-19 - PubMed
  10. Diabetes. 2012 Apr;61(4):888-96 - PubMed
  11. Am Heart J. 1998 Apr;135(4):592-7 - PubMed
  12. Eur Heart J. 2012 Jun;33(12):1491-9 - PubMed
  13. Diabetologia. 2012 Apr;55(4):926-35 - PubMed
  14. J Hypertens. 2013 Jun;31(6):1061-72 - PubMed
  15. J Card Fail. 1997 Jun;3(2):83-9 - PubMed
  16. Horm Metab Res. 2008 Sep;40(9):593-606 - PubMed
  17. Clin Physiol. 1988 Apr;8(2):155-62 - PubMed
  18. Am J Cardiol. 1995 Oct 1;76(10):679-83 - PubMed
  19. Lancet. 2003 Jul 26;362(9380):316-22 - PubMed
  20. Circulation. 2004 Mar 2;109(8):962-5 - PubMed
  21. Am J Physiol Endocrinol Metab. 2004 Dec;287(6):E1209-15 - PubMed
  22. Endocr Connect. 2014 Jan 21;3(1):11-6 - PubMed
  23. Regul Pept. 2005 Feb 15;125(1-3):173-7 - PubMed
  24. Biochem J. 1987 Jan 1;241(1):265-72 - PubMed
  25. Am J Physiol Regul Integr Comp Physiol. 2002 Jul;283(1):R257-65 - PubMed
  26. Lancet. 2006 Nov 11;368(9548):1696-705 - PubMed
  27. Diabetes Care. 2015 Jan;38(1):132-9 - PubMed
  28. Circulation. 2004 Aug 24;110(8):955-61 - PubMed
  29. J Hypertens. 1994 Apr;12(4):329-36 - PubMed
  30. Kidney Int. 1992 May;41(5):1333-9 - PubMed
  31. J Hypertens. 2003 Jun;21(6):1125-35 - PubMed
  32. Diabetes Care. 2015 Jan;38(1):e7-8 - PubMed
  33. Eur J Heart Fail. 2004 Mar 15;6(3):309-12 - PubMed

Publication Types